Literature DB >> 9093585

Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10.

M J Allen1, B J Myer, A M Khokher, N Rushton, T M Cox.   

Abstract

Gaucher's disease is characterized by hepatosplenomegaly, bone-marrow infiltration, osteonecrosis and bone thinning, associated with the presence of pathological macrophages that contain undegraded glycosphingolipids. To investigate the possible role of cytokines in the systemic and local manifestations of established Gaucher's disease, interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF alpha) and interleukin-10 (IL-10) were measured in freshly-separated serum. Samples from eight male and 14 female patients with type 1 Gaucher's disease were compared with sera from 22 healthy age- and sex-matched controls. Concentrations of IL-6 and IL-10 were significantly elevated in sera from patients with Gaucher's disease (11.9 +/- 1.8 (SEM) pg/ml and 5.4 +/- 0.5 (SEM) pg/ml, respectively) compared with those of controls (4.1 +/- 0.9 (SEM) and 0.8 +/- 0.3 (SEM) pg/ml, p < 0.0001). No significant differences in concentrations of TNF alpha or IL-1 beta were identified. IL-6 has been implicated in the development of localized osteolysis in multiple myeloma and in the development of post-menopausal osteoporosis. High concentrations of IL-6 in the serum of patients with Gaucher's disease may thus reflect the development of the bone lesions commonly associated with this disorder. Since IL-6 and IL-10 are important regulators of lymphocyte growth and differentiation, and IL-6 concentrations were significantly raised in patients with oligo- or polyclonal increases in serum immunoglobulins, enhanced release of these cytokines from pathological macrophages provides a pathological link between Gaucher's disease and associated lympho-proliferative disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9093585     DOI: 10.1093/qjmed/90.1.19

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  58 in total

1.  Gaucher disease gene GBA functions in immune regulation.

Authors:  Jun Liu; Stephanie Halene; Mei Yang; Jameel Iqbal; Ruhua Yang; Wajahat Z Mehal; Wei-Lien Chuang; Dhanpat Jain; Tony Yuen; Li Sun; Mone Zaidi; Pramod K Mistry
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

2.  Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.

Authors:  Sarah M Lo; Philip Stein; Sean Mullaly; Michael Bar; Dhanpat Jain; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2010-05       Impact factor: 10.047

Review 3.  Common and uncommon pathogenic cascades in lysosomal storage diseases.

Authors:  Einat B Vitner; Frances M Platt; Anthony H Futerman
Journal:  J Biol Chem       Date:  2010-04-29       Impact factor: 5.157

4.  Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy.

Authors:  G Ciana; R Addobbati; G Tamaro; A Leopaldi; M Nevyjel; L Ronfani; L Vidoni; M G Pittis; B Bembi
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

5.  Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability.

Authors:  Raquel L Lieberman; J Alejandro D'aquino; Dagmar Ringe; Gregory A Petsko
Journal:  Biochemistry       Date:  2009-06-09       Impact factor: 3.162

6.  IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: a case report.

Authors:  C Martinez-Redondo; F J Ortuño; M L Lozano; A Jerez; M del Mar Osma; P Giraldo; V Vicente
Journal:  J Inherit Metab Dis       Date:  2009-06-27       Impact factor: 4.982

7.  A branch retinal artery occlusion in a patient with Gaucher disease.

Authors:  Alice Bruscolini; Maria Pia Pirraglia; Lucia Restivo; Giovanni Spinucci; Alessandro Abbouda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-02       Impact factor: 3.117

8.  Neonatal cholestasis as initial manifestation of type 2 Gaucher disease: a continuum in the spectrum of early onset Gaucher disease.

Authors:  Abdallah F Elias; Maria Ronningen Johnson; John K Boitnott; David Valle
Journal:  JIMD Rep       Date:  2011-12-11

9.  Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation.

Authors:  Shiny Nair; Chandra Sekhar Boddupalli; Rakesh Verma; Jun Liu; Ruhua Yang; Gregory M Pastores; Pramod K Mistry; Madhav V Dhodapkar
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

10.  Life expectancy in Gaucher disease type 1.

Authors:  Neal J Weinreb; Patrick Deegan; Katherine A Kacena; Pramod Mistry; Gregory M Pastores; Priscilla Velentgas; Stephan vom Dahl
Journal:  Am J Hematol       Date:  2008-12       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.